Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold ...

While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

Competition from the bispecifics could be a big deal for MSD – known as Merck & Co in the US and Canada – given that Keytruda contributed $25 billion of its $60.1 billion global sales last year.

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

"The idea that we are in a digestion phase for AI is laughable given the obvious need for more inference chips," Morgan ...

Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes ...

Merck, known as MSD outside the US and Canada, got approval for Vaxneuvance from the FDA in July – a month after Pfizer upped the ante in the competitive stakes with a green light for Prevnar-20 ...